




Healthcare Industry News: ProBeam
News Release - May 24, 2017
Varian Selected to Provide First Proton Therapy System in Thailand
PALO ALTO, Calif., May 24, 2017 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (NYSE: VAR), today announced it has been selected through its distributor, Business Alignment, to supply and install a Varian ProBeam® Compact single-room proton therapy system in the oncology center at King Chulalongkorn Memorial Hospital in Bangkok, Thailand. First patient treatments are expected to start in the second half of 2019. In addition to the equipment, Varian will also provide its Eclipse™ treatment planning system and ARIA® information management system. Varian is booking the order for the equipment in the third quarter of its fiscal year 2017."We selected the Varian system because of the company's history of innovation in cancer treatment and the technical advances in this system and the integration with ARIA and Eclipse," said Dr. Chonlakiet Khorprasert, King Chulalongkorn Memorial Hospital. "We look forward to working closely with Varian to bring this advanced cancer-fighting technology to Thailand."
"We are excited by this opportunity to expand access to proton therapy in Thailand," said Dr. Moataz Karmalawy, general manager of Varian's Particle Therapy division. "By giving our Compact system all the technical capabilities of our multi-room ProBeam systems, clinics around the world are realizing they can install an advanced system that can fit in small locations and deliver high quality care without compromise."
About Varian Medical Systems
Varian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,400 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.